The FDA has granted accelerated approval for zenocutuzumab-zbco (Bizengri) to treat certain adults with non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma who have a neuregulin 1 (NRG1) gene fusion. The approval was based on a study showing an overall response rate of 33% in NSCLC patients and 40% in pancreatic adenocarcinoma patients. Common adverse reactions included diarrhea, musculoskeletal pain, and fatigue. The agent is the only approved NRG1+ therapy for these cancers. The recommended dose is 750 mg every 2 weeks. The FDA approval is seen as an important milestone for patients with advanced NSCLC or pancreatic adenocarcinoma.
Source link
FDA Approves Bizengri for NSCLC, Pancreatic Cancer
